Menu Search
Equities

Genmab A/S

GMAB:NSQ

Genmab A/S

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)20.47
  • Today's Change0.02 / 0.10%
  • Shares traded1.51m
  • 1 Year change-33.97%
  • Beta0.9648
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy1
Outperform4
Hold5
Sell0
Strong Sell0

Share price forecast in USD

The 10 analysts offering 12 month price targets for Genmab A/S - ADR have a median target of 37.25, with a high estimate of 51.00 and a low estimate of 25.00. The median estimate represents a 81.97% increase from the last price of 20.47.
High149.1%51.00
Med82.0%37.25
Low22.1%25.00

Earnings history & estimates in USD

On Nov 06, 2024, Genmab A/S - ADR reported 3rd quarter 2024 earnings of 0.292 per share.
The next earnings announcement is expected on Feb 12, 2025.
Average growth rate+9.85%
Genmab A/S - ADR reported annual 2023 earnings of 0.958 per share on Feb 14, 2024.
Average growth rate-17.13%
More ▼

Revenue history & estimates in USD

Genmab A/S - ADR had 3rd quarter 2024 revenues of 815.85m. This missed the 835.38m consensus estimate of the 7 analysts following the company. This was 98.25% above the prior year's 3rd quarter results.
Average growth rate+5.18%
Genmab A/S - ADR had revenues for the full year 2023 of 2.39bn. This was 15.99% above the prior year's results.
Average growth rate+37.08%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.